Status:
COMPLETED
Validation of a New Device to Measure Neuromuscular Disease Progression
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Eligibility:
All Genders
18+ years
Brief Summary
There is a great need for the development of sensitive outcomes that allow experimental drugs to be tested in human subjects more efficiently. If we could more precisely measure whether an experimenta...
Eligibility Criteria
Inclusion
- All subjects must be at least 18 years old and able to provide informed consent
- All subjects have no health conditions that limit their ability to safely exert maximal force using the muscles in their arms and legs.
- Subjects with a diagnosis of laboratory supported probable, probable or definite ALS according to the World Federation of Neurology El Escorial, as determined by their referring neurologist at MGH.
- All subjects must be able to speak and understand English.
Exclusion
- Presence of significant arthritis, orthopedic conditions, or cardio-pulmonary conditions or other medical conditions that may limit the ability to maximally exert force safely.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2010
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00606918
Start Date
January 1 2008
End Date
September 1 2010
Last Update
May 12 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital - East
Charlestown, Massachusetts, United States, 02129